Spatial Concept – Page 3 – Talk Bio

Actionable Insights Powered by AI

iTeos to Shut Down Operations After TIGIT Therapy Setback

5 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved

5 months ago talkbio0Tagged CEO, Clinical Trials, Exit, gene therapy, layoffs, pipeline pivot, PM359, Prime Editing, Prime Medicine, restructuring

Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

5 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

6 months ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

Roche could rethink $50B US expansion plan if new policies ‘harm’ operations

6 months ago talkbio0Tagged expansion, Infantile Neuroaxonal Dystrophy, Investments, Policy, Roche (company), United States

Roche (company), United States, Investments, expansion, Policy, Infantile Neuroaxonal Dystrophy

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

6 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

Protect Your Trial Data: Endpoint, Imaging, and Safety Review

6 months ago talkbio0Tagged Biomechanical compliance, Clinical Trials, CTMS, Diagnostic Imaging, Encryption, End Point, General Data Protection Regulation, safety review, Security - service

Clinical Trials, Diagnostic Imaging, Security – service, End Point, safety review, General Data Protection Regulation, Biomechanical compliance, CTMS, Encryption

Trump, FDA zero in on foreign factories to give domestic sites an edge

6 months ago talkbio0Tagged foreign factories, manufacturers, Transplant Registry Unified Management Program, United States, United States Food and Drug Administration

United States Food and Drug Administration, United States, Transplant Registry Unified Management Program, foreign factories, manufacturers

‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

6 months ago talkbio0Tagged Drug Industry, Health Care Reform, Home environment, Manufacturing, Myers, pharmaceutical manufacturing, pharmaceutical tariffs, squibb, Trump tariffs, U.S.

Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs

Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact

6 months ago talkbio0Tagged Alchemab, Amyotrophic Lateral Sclerosis, Eli, Eli Lilly

Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly